Technical Analysis for BHVN - Biohaven Pharmaceutical Holding Company Ltd.

Grade Last Price % Change Price Change
C 92.98 -0.25% -0.23
BHVN closed down 0.25 percent on Wednesday, June 16, 2021, on 2.5 times normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical BHVN trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Multiple of Ten Bearish Other -0.25%
Wide Bands Range Expansion -0.25%
Overbought Stochastic Strength -0.25%
Slingshot Bullish Bullish Swing Setup -7.39%
Wide Bands Range Expansion -7.39%
Overbought Stochastic Strength -7.39%
Older End-of-Day Signals for BHVN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Pocket Pivot about 4 hours ago
Down 2 % about 6 hours ago
60 Minute Opening Range Breakdown about 6 hours ago
Possible NR7 about 6 hours ago
60 Minute Opening Range Breakout about 9 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Biohaven Pharmaceutical Holding Company Ltd. Description

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Chemical Compounds Organic Compounds Neuroscience Degenerative Disease Degenerative Diseases Neurodegenerative Diseases Glutamate Riluzole

Is BHVN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 106.565
52 Week Low 57.66
Average Volume 563,472
200-Day Moving Average 79.36
50-Day Moving Average 78.89
20-Day Moving Average 88.52
10-Day Moving Average 96.02
Average True Range 4.27
ADX 40.31
+DI 34.98
-DI 22.93
Chandelier Exit (Long, 3 ATRs) 93.75
Chandelier Exit (Short, 3 ATRs) 80.89
Upper Bollinger Bands 106.63
Lower Bollinger Band 70.41
Percent B (%b) 0.62
BandWidth 40.91
MACD Line 6.14
MACD Signal Line 5.81
MACD Histogram 0.3229
Fundamentals Value
Market Cap 5.57 Billion
Num Shares 59.9 Million
EPS -9.14
Price-to-Earnings (P/E) Ratio -10.17
Price-to-Sales 181.98
Price-to-Book 31.82
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 98.70
Resistance 3 (R3) 98.64 96.67 97.74
Resistance 2 (R2) 96.67 95.22 96.70 97.42
Resistance 1 (R1) 94.83 94.32 93.85 94.89 97.11
Pivot Point 92.86 92.86 92.37 92.89 92.86
Support 1 (S1) 91.02 91.41 90.04 91.08 88.85
Support 2 (S2) 89.05 90.51 89.08 88.54
Support 3 (S3) 87.21 89.05 88.22
Support 4 (S4) 87.27